 SOUTH SAN FRANCISCO, Calif. and PARIS, April 28, 2021 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer, in collaboration with its development partner Servier, an independent international pharmaceutical company, today announced that longer-term follow-up data from Allogenes dose escalation Phase 1 ALPHA study of ALLO-501 in relapsedrefractory non-Hodgkin lymphoma NHL will be jointly presented with initial data from the ALPHA2 trial of ALLO-501A at the 2021 American Society of Clinical Oncology ASCO Annual Meeting being held virtually June 4 - 9, 2021. A separate poster presentation will detail safety and biomarker findings from ALLO-647, Allogenes wholly owned antibody used for lymphodepletion with fludarabine Flucyclophosphamide Cy in patients with relapsedrefractory non-Hodgkin lymphoma and multiple myeloma. 